Organisation paid for research Program year 2021 Source: CMS Open Payments

Sols Through Advanced Research Inc

Neither a doctor nor a teaching hospital

Research payments

$401,042

122 payments

Through program year 2021, Sols Through Advanced Research Inc is reported as receiving $401,042 in research payments, across 122 payments.

By program year

3 rows
Year Kind Amount Payments
2021 Research $123,805 51
2020 Research $108,314 36
2019 Research $168,923 35

Breakdown

Who paid Research payments · program years 2019–2021
  1. AbbVie, Inc. $401,042 122 payments
Studies the money was for Research payments · program years 2019–2021
  1. M14-702 $128,806 24 payments
  2. M16-100 $83,726 21 payments
  3. A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain $31,178 13 payments
  4. M19-977 $29,348 4 payments
  5. A Randomized, Active-Controlled, Efficacy Assessor-Blinded Study to Evaluate Pharmacokinetics, Safety and Efficacy of Risankizumab in Patients from 6 to Less Than 18 Years of Age with Moderate to Severe Plaque Psoriasis $26,808 9 payments
  6. A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain $26,280 6 payments
  7. M16-283 $25,441 15 payments
  8. Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study $16,860 11 payments
  9. OptIMMize-2: A Phase 3 Multicenter, Single-arm, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Risankizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Completed Participation in Study M19-977 (OptIMMize-1) $10,500 1 payment
  10. A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women $7,777 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2021

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record